MHC antigens and tumor escape from immune surveillance (Q34414647)

2 August 2017

1 reference

title

MHC antigens and tumor escape from immune surveillance (English)

1 reference

2 August 2017

Garrido F

1

1 reference

2 August 2017

Algarra I

series ordinal

2

1 reference

2 August 2017

publication date

1 January 2001

1 reference

Advances in Cancer Research

2 August 2017

published in

1 reference

2 August 2017

volume

83

1 reference

2 August 2017

page(s)

117-158

1 reference

Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Viral mechanisms of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

NK sensitivity and lung clearance of MHC-class-I-deficient cells within a heterogeneous fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The HLA crossroad in tumor immunology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Strong HLA-DR expression in large bowel carcinomas is associated with good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Cytogenetics of carcinoma of the cervix uteri: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Mutations of the beta2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of HLA class I expression in prostate cancer: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Tumor antigens recognized by T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Multiple mechanisms underlie HLA dysregulation in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immune surveillance in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Phenotypic dynamics of tumor progression in human malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Mechanisms of loss of HLA class I expression on colorectal tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of HLA-D subloci DR and DQ by breast carcinomas is correlated with distinct parameters of favourable prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immunohistochemical studies on the expression of HLA class I antigens in renal cell carcinoma: comparison of primary and metastatic tumor tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Biological implications of HLA-DR expression in tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

High frequency of altered HLA class I phenotypes in invasive breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

High frequency of altered HLA class I phenotypes in laryngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Structural and functional analysis of beta2 microglobulin abnormalities in human lung and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Presentation of endogenous tumor antigens to CD4+ T lymphocytes by murine melanoma cells transfected with major histocompatibility complex class II genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The host-tumor immune conflict: from immunosuppression to resistance and destruction

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Different patterns of HLA-DR antigen expression in normal epithelium, hyperplastic and neoplastic malignant lesions of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of MHC class-I expression in cervical carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Antitumor immunity at work in a melanoma patient

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The detailed distribution of HLA-A, B, C antigens in normal human organs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immunohistological evaluation of MHC class I and II antigen expression on nevi and melanoma: relation to biology of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Recent advances in breast cancer biology

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Histocompatibility antigens in primary and metastatic squamous cell carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A genetic model for colorectal tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Mutation in the beta 2m gene is not a frequent event in head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I expression and chromosomal deletions at 6p and 15q in head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Microsatellite analysis of microdissected tumor cells and 6p high density microsatellite analysis in head and neck squamous cell carcinomas with down-regulated human leukocyte antigen class I expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I and II expression in rhabdomyosarcomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

MHC class I and II antigens on gastric carcinomas and autologous mucosa

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The biological consequences of altered MHC expression on tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Tumour immunology: MHC antigens and malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Distribution of HLA class 1 antigens in normal human tissue and in mammary cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Further evidence for depression of H-2 and Ia-like specificities of foreign haplotypes in mouse tumour cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Natural history of HLA expression during tumour development.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Structure of the HLA class I region and expression of its resident genes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Class II HLA antigen expression in familial polyposis coli is related to the degree of dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

An evaluation of the prognostic significance of HLA-DR expression in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

High frequency of allele-specific down-regulation of HLA class I expression in uveal melanoma cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Allelic loss and prognosis in carcinoma of the uterine cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Human leukocyte antigen class I gene mutations in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA-G: on the track of immunological functions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of HLA class I-encoded cell surface antigens in transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Differential expression of HLA class I and II antigens in primary and metastatic melanomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I gene expression on human primary tumours and autologous metastases: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Prognostic significance of the histological features of malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

B-cell lymphomas of high-grade malignancy frequently lack HLA-DR, -DP and -DQ antigens and associated invariant chain.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Receptors for HLA class-I molecules in human natural killer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Low Frequency of ErbB-2 Proto-oncogene Overexpression in Human Leukocyte Antigen-A2-Positive Breast Cancer Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Modulation of HLA-G antigens expression by human cytomegalovirus: specific induction in activated macrophages harboring human cytomegalovirus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of MHC Class II and B7-1 and B7-2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

PHENOTYPIC HETEROGENEITY OF HLA PRODUCTS ON HUMAN MELANOMA CELLS

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Transcriptional suppression of HLA-B expression by c-Myc is mediated through the core promoter elements

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Prognostic factors in laryngeal carcinoma. A multifactorial study of 416 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A new beta 2 microglobulin mutation found in a melanoma tumor cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A weakly tumorigenic phenotype with high MHC class-I expression is associated with high metastatic potential after surgical removal of the primary murine fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Criteria to define HLA haplotype loss in human solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Molecular strategies to define HLA haplotype loss in microdissected tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

In vivo and in vitro generation of a new altered HLA phenotype in melanoma-tumour-cell variants expressing a single HLA-class-I allele

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of HLA G in human tumors is not a frequent event.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Identification of human cancers deficient in antigen processing

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Upmodulation by estrogen of HLA class I expression in breast tumor cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA and cancer: from research to clinical impact

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Molecular characterization of defective antigen processing in human prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A mutation determining the loss of HLA-A2 antigen expression in a cervical carcinoma reveals novel splicing of human MHC class I classical transcripts in both tumoral and normal cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Transfection of TAP 1 gene restores HLA class I expression in human small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

SELECTIVE LOSS OF HLA-A,B,C LOCUS PRODUCTS IN COLORECTAL ADENOCARCINOMA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Reduction of major histocompatibility complex class I antigens on invasive and high-grade transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Regulation of T cell function by NK cell receptors for classical MHC class I molecules.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

1 reference

7 January 2021

Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

1 reference

7 January 2021

Lacking prognostic significance of beta 2-microglobulin, MHC class I and class II antigen expression in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Expression of markers for transitional cell carcinoma in normal bladder mucosa of patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Carcinogenesis and natural selection: a new perspective to the genetics and epigenetics of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Can the HLA phenotype be used as a prognostic factor in breast carcinomas?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Heterogeneity of the expression of class I and II HLA antigens in human breast carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

Molecular analysis of MHC-class-I alterations in human tumor cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-230X%2801%2983005-0

7 January 2021

10.1016/S0065-230X(01)83005-0

Identifiers

DOI

1 reference

2 August 2017

1 reference